Add to ORKGHendrikse, N.H. [Promotor]Heine, R. ter [Copromotor]Klerk, J.M.H. de [Copromotor]Bloemendal, H.J. [Copromotor
The availability of therapeutic radioisotopes at reasonable costs is important for applications in n...
AIM: Rhenium-188-HEDP ((188)Re-HEDP) is an effective radiopharmaceutical for the palliative treatmen...
Radiopharmaceuticals are radioactive medications (radioisotopes) and are composed of radionuclidic a...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Rhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-l...
Systemic use of radiopharmaceuticals is a recognized alternative method for the treatment of pain in...
In this report the authors describe the use of an effective method for concentration of the rhenium-...
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, a...
Rhenium-188-hydroxyethylidine diphosphonate(188Re-HEDP) is a novel and attractive radiopharmaceutica...
INTRODUCTION: (188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for ...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion elec...
Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for tr...
The availability of therapeutic radioisotopes at reasonable costs is important for applications in n...
AIM: Rhenium-188-HEDP ((188)Re-HEDP) is an effective radiopharmaceutical for the palliative treatmen...
Radiopharmaceuticals are radioactive medications (radioisotopes) and are composed of radionuclidic a...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Rhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-l...
Systemic use of radiopharmaceuticals is a recognized alternative method for the treatment of pain in...
In this report the authors describe the use of an effective method for concentration of the rhenium-...
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, a...
Rhenium-188-hydroxyethylidine diphosphonate(188Re-HEDP) is a novel and attractive radiopharmaceutica...
INTRODUCTION: (188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for ...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion elec...
Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for tr...
The availability of therapeutic radioisotopes at reasonable costs is important for applications in n...
AIM: Rhenium-188-HEDP ((188)Re-HEDP) is an effective radiopharmaceutical for the palliative treatmen...
Radiopharmaceuticals are radioactive medications (radioisotopes) and are composed of radionuclidic a...